169 related articles for article (PubMed ID: 29399388)
1. T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.
Doorduijn EM; Sluijter M; Marijt KA; Querido BJ; van der Burg SH; van Hall T
Oncoimmunology; 2018; 7(3):e1382793. PubMed ID: 29399388
[TBL] [Abstract][Full Text] [Related]
2. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
[TBL] [Abstract][Full Text] [Related]
3. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
[TBL] [Abstract][Full Text] [Related]
4. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
6. TAP-ing into TIEPPs for cancer immunotherapy.
Kiessling R
J Clin Invest; 2016 Feb; 126(2):480-2. PubMed ID: 26784539
[TBL] [Abstract][Full Text] [Related]
7. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.
Seidel UJ; Oliveira CC; Lampen MH; Hall Tv
Cancer Immunol Immunother; 2012 Jan; 61(1):119-25. PubMed ID: 22116347
[TBL] [Abstract][Full Text] [Related]
8. The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.
Hafstrand I; Doorduijn EM; Sun R; Talyzina A; Sluijter M; Pellegrino S; Sandalova T; Duru AD; van Hall T; Achour A
J Immunol; 2018 Apr; 200(8):2860-2868. PubMed ID: 29507106
[TBL] [Abstract][Full Text] [Related]
9. Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire.
Oliveira CC; Sluijter M; Querido B; Ossendorp F; van der Burg SH; van Hall T
Mol Immunol; 2014 Nov; 62(1):129-36. PubMed ID: 24983205
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-Mediated Inhibition of the Transporter Associated with Antigen Processing Is Insufficient To Induce Major Histocompatibility Complex E-Restricted CD8
Abdulhaqq SA; Wu H; Schell JB; Hammond KB; Reed JS; Legasse AW; Axthelm MK; Park BS; Asokan A; Früh K; Hansen SG; Picker LJ; Sacha JB
J Virol; 2019 Oct; 93(19):. PubMed ID: 31315990
[TBL] [Abstract][Full Text] [Related]
11. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
12. The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer.
Hafstrand I; Doorduijn EM; Duru AD; Buratto J; Oliveira CC; Sandalova T; van Hall T; Achour A
J Immunol; 2016 Mar; 196(5):2327-34. PubMed ID: 26800871
[TBL] [Abstract][Full Text] [Related]
13. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival.
Lou Y; Basha G; Seipp RP; Cai B; Chen SS; Moise AR; Jeffries AP; Gopaul RS; Vitalis TZ; Jefferies WA
Clin Cancer Res; 2008 Mar; 14(5):1494-501. PubMed ID: 18316574
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
15. CD4
Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
[TBL] [Abstract][Full Text] [Related]
16. Selected HLA-B allotypes are resistant to inhibition or deficiency of the transporter associated with antigen processing (TAP).
Geng J; Zaitouna AJ; Raghavan M
PLoS Pathog; 2018 Jul; 14(7):e1007171. PubMed ID: 29995954
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.
Aladin F; Lautscham G; Humphries E; Coulson J; Blake N
Cancer Immunol Immunother; 2007 Aug; 56(8):1143-52. PubMed ID: 17143611
[TBL] [Abstract][Full Text] [Related]
18. Self peptide/MHC class I complexes have a negligible effect on the response of some CD8+ T cells to foreign antigen.
Spörri R; Reis e Sousa C
Eur J Immunol; 2002 Nov; 32(11):3161-70. PubMed ID: 12555661
[TBL] [Abstract][Full Text] [Related]
19. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
20. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.
Marijt KA; Sluijter M; Blijleven L; Tolmeijer SH; Scheeren FA; van der Burg SH; van Hall T
J Immunother Cancer; 2019 Jun; 7(1):152. PubMed ID: 31196219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
